Theleme Partners LLP
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 13, 2025), Theleme Partners LLP reported 10 stock positions worth $1.6 billion. Its top holding was Meta Platforms Class A (META) at 17.0% of the portfolio, followed by Wells Fargo (WFC, 14.6%) and Moderna (MRNA, 13.3%). Compared with Q2 2025, it opened 1 new position, sold out of 1, added to 4 and reduced 5. The biggest buy was Meta Platforms Class A (META, shares +34%) and the biggest sale Bank of America (BAC, shares −39%).
- Most Recent 13F
- Q2 2026
- Location
- London, X0
- CIK
- 0001511881
- Portfolio Value
- $1.6B (Q3 2025)
- SEC Filing
- 0000919574-25-006668 ↗ filed Nov 13, 2025
Holdings Value
Holdings 10 stocks · $1.6B
| META Meta Platforms Inc. Class A | 17.02% | 362,675 | $266.3M | Add +33.8% |
| WFC Wells Fargo & Co. | 14.65% | 2,733,840 | $229.2M | Add +3.4% |
| MRNA Moderna Inc. | 13.32% | 8,068,810 | $208.4M | Add +2.5% |
| TRU Transunion | 11.95% | 2,230,882 | $186.9M | Add +5.8% |
| UBER Uber Technologies Inc. | 9.72% | 1,552,250 | $152.1M | Reduce -8.1% |
| FLUT Flutter Entertainment PLC-Di | 9.03% | 556,041 | $141.2M | Reduce -13.6% |
| EFX Equifax Inc. | 8.30% | 506,088 | $129.8M | Reduce -15.4% |
| AMZN Amazon.com Inc. | 7.92% | 563,979 | $123.8M | Reduce -18.0% |
| BAC Bank of America Corp. filed as BANK AMERICA CORP | 7.23% | 2,192,660 | $113.1M | Reduce -38.9% |
| SIFY Sify Technologies-Spon ADR | 0.87% | 997,583 | $13.6M | New |
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $1.7B | MRNA, META, UBER, AMZN, TRU |
| Q1 2026 | 9 | $1.5B | MRNA, META, UBER, TRU, AMZN |
| Q4 2025 | 9 | $1.5B | META, MRNA, FLUT, TRU, WFC |
| Q3 2025 | 10 | $1.6B | META, WFC, MRNA, TRU, UBER |
| Q2 2025 | 10 | $1.6B | MRNA, WFC, META, TRU, FLUT |
| Q1 2025 | 12 | $1.3B | MRNA, AMZN, WFC, TRU, EFX |
| Q4 2024 | 11 | $1.5B | MRNA, BAC, WFC, AMZN, EFX |
| Q3 2024 | 10 | $1.7B | MRNA, SCHW, TRU, EFX, HRI |
| Q2 2024 | 8 | $2.0B | MRNA, SCHW, WFC, TRU, HRI |
| Q1 2024 | 7 | $1.8B | MRNA, SCHW, WFC, HRI, TRU |